#China #Shanghai #Drug Discovery #Viva Biotech #AIDD

Viva Biotech Unveils a Groundbreaking AI-Driven Drug Discovery Platform

On May 13, 2025, at the enchanting event dubbed "Enchantment of Drug Discovery," Viva Biotech revealed its latest advancement: an AI-Driven Drug Discovery (AIDD) platform. This cutting-edge technology promises to revolutionize the research and development logic behind new drug formulations, enabling a seamless and innovative approach to drug discovery. According to Dr. Yue Qian, Executive Director at Viva Biotech, this platform is designed to streamline processes and inject a new level of intelligence into the pharmaceutical landscape.

The AIDD platform features three main components: V-Scepter, V-Orb, and V-Mantle. Each of these modules plays a crucial role in enhancing the drug discovery process. For instance, V-Scepter allows users to conduct advanced molecular modeling with state-of-the-art computational tools, while V-Orb leverages augmented virtual screening techniques to improve screening efficiency. V-Mantle incorporates large language models that facilitate complex structure predictions and automated workflows necessary for antibody engineering.

Harnessing the Power of Structure-Based Drug Discovery

Viva's extensive 15-year experience in structure-based drug discovery (SBDD) lays a solid foundation for the AIDD platform. The company combines high-throughput affinity-based screening with sophisticated biochemical assays and a dedicated medicinal chemistry team. This unique blend of expertise ensures that the AI algorithms driving the platform are built on robust structural insights, allowing for rapid identification of new molecular targets and mechanisms.

Traditionally, drug discovery is a lengthy and expensive process, often taking 2-4 years from candidate selection to clinical trials. However, the introduction of AI technologies has the potential to drastically reduce this time frame. The AIDD platform can streamline candidate design workflows to less than two years while slashing development costs by up to 70%.

New Workflow for Antibody Discovery

In addition to small molecules, the AIDD platform expands its capabilities to biologics by introducing an AI-powered antibody design workflow. By initiating with AI-generated antibody sequences, the platform can accelerate the design process, allowing researchers to bypass the extensive traditional screening methods. The rapid validation and iterative feedback loop enhance the success rate, ensuring that candidates are optimized efficiently.

Dr. Qian emphasizes that the AIDD platform does not merely rely on AI; it integrates comprehensive data sets, algorithms, and molecular structures to facilitate a more effective drug development process.

Demonstrating the Platform's Capabilities

During the launch event, several live demonstrations showcased the AIDD platform's capabilities. The ADMET prediction tool was highlighted for its impressive correlation with experimental data, illustrating the reliability of the underlying models. Furthermore, proprietary molecular dynamics techniques were introduced, which can optimize covalent interactions, showcasing the integration of quantum mechanics with dynamic sampling.

In the realm of antibody design, V-Mantle's workflow combines advanced structure prediction and iterative designs, ensuring a thorough evaluation of each candidate's druglike properties, including affinity and developability.

Conclusion

As the pharmaceutical industry continues to evolve, Viva Biotech's AIDD platform represents a significant leap forward. By bridging the traditional gaps between discovery and development, the platform empowers scientists to conduct research with unprecedented speed and accuracy. Dr. Qian concluded by stating, "The integration of data and AI in drug discovery enables us to overcome existing barriers, transforming once-considered impossible tasks into possible breakthroughs." The future of drug development is here, and with Viva Biotech leading the charge, the industry may witness unprecedented advancements in therapeutic innovations.